Search Results

You are looking at 161 - 170 of 2,671 items for :

  • Refine by Access: All x
Clear All
Full access

Akhil Jain, Sohiel Deshpande, Krishna Desai, Sabah Iqbal, Aisha Sultan, Monika Garg, Bohdan Baralo, and Rajesh Thirumaran

analyze the regional disparities in the outcomes of hospitalized FN patients. Methods: Using NIS 2016-19 datasets, we identified chemotherapy related FN hospitalizations (ICD-10-CM codes) and analyzed (weighted) for differences in demographics, admitting

Full access

Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin

most patients with UCRP are elderly and many have had prior radical nephroureterectomy, the concern for renal toxicity frequently limits the use of these chemotherapeutic regimens. 11 The poor outcomes and significant toxicities associated with first

Full access

Sai-Ching Yeung, Aiham Qdaisat, Mona Kamal, Aisha Al-Breiki, Biman Goswami, Carol C. Wu, Shouhao Zhou, Terry Rice, and Kumar Alagapan

Incidental pulmonary embolisms (IPE) are commonly discovered in cancer patients during their cancer staging and surveillance imaging studies. Examining the clinical characteristics and outcomes of these incidents in cancer patients may guide the

Full access

Amy Chieng, Maura Chandler, Cindy Tran, Brittany Pike, Alexandra Liu, LittleDove Faith Rey, Lauren Haruno, Annemarie Jagielo, Amy Pirkl, and Judith J Prochaska

cessation treatment into cancer care. The funding, technical, and peer support from the C3I collaboration was instrumental in extending Stanford’s tobacco treatment service into 20+ clinics across 3 cancer centers. Aim : To report on patient outcomes at 6

Full access

Marwah W. Farooqui, Caitlin Carter, Nicholas Gustafson, Saherish Abbasi, Sravani Sagireddy, Kathryn Hockensmith, Amy Stein, Masood Ghouse, and Krishan Srinivasan

Obesity has an association with triple negative breast cancer (TNBC). Healthy diet, weight loss, and exercise have lead to favorable outcomes (overall survival [OS], progression free survival [PFS],quality of life [QOL])in TNBC. We aim to highlight

Full access

Luis Aguirre, Jacques Fontaine, Jessica Frakes, Sarah Hoffe, Jose Pimiento, and Rutika Mehta

of cardiac comorbidities impacted the outcomes of patients who underwent trimodality therapy for esophageal cancer. Methods: After IRB approval, we collected data on patients treated at our center for locally advanced disease and received

Full access

Patricia I. Moreno, Frank J. Penedo, Felicia M. Knaul, Carina Oltmann, Michael T. Huber, and Mariana Khawand-Azoulai

The aim of systematic symptom screening and monitoring using patient-reported outcomes (PROs) is to collect actionable data and provide responsive care that is centered around patients’ needs. Recent evidence demonstrates that routine assessment

Full access

Grant R. Williams, Marc S. Weinberg, and Shlomit S. Shachar

dichotomizing participants as high or low radiodensity, why not integrate these 2 variables into 1 continuous variable? Because both muscle mass and radiodensity are defined independently and both are prognostic of many adverse cancer outcomes, we have proposed

Full access

Yunyun Liu, KKL Chan, and Hui Zhou

relapse, indicating that the poorer outcome of patients with NACT>3 may not be caused by chemo-induced resistance. The reason of worse outcomes after more cycles of NACT is still needed to be explored. CLO22-060 Figure 1 CLO22-060 Table 1

Full access

Stephenie Kennedy-Rea, Adrienne Duckworth, Amy Reasinger Allen, and Samaneh Kalirai

decrease the consequences of treatment. In this analysis, we summarize the program outcomes and provide an economic perspective on implementation and sustainability. The Bridge Program enrolls and assesses patients at the end of cancer treatment using a